HUM vs. CNC, MOH, CI, ELV, IQV, TAK, IDXX, ALC, COR, and HLN
Should you be buying Humana stock or one of its competitors? The main competitors of Humana include Centene (CNC), Molina Healthcare (MOH), The Cigna Group (CI), Elevance Health (ELV), IQVIA (IQV), Takeda Pharmaceutical (TAK), IDEXX Laboratories (IDXX), Alcon (ALC), Cencora (COR), and Haleon (HLN). These companies are all part of the "medical" sector.
Humana (NYSE:HUM) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Humana has a net margin of 1.82% compared to Centene's net margin of 1.76%. Humana's return on equity of 17.76% beat Centene's return on equity.
Humana presently has a consensus target price of $424.50, suggesting a potential upside of 19.32%. Centene has a consensus target price of $85.23, suggesting a potential upside of 9.19%. Given Humana's higher probable upside, equities research analysts plainly believe Humana is more favorable than Centene.
Humana has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
Centene received 129 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.25% of users gave Centene an outperform vote while only 64.15% of users gave Humana an outperform vote.
In the previous week, Humana had 4 more articles in the media than Centene. MarketBeat recorded 22 mentions for Humana and 18 mentions for Centene. Centene's average media sentiment score of 0.84 beat Humana's score of 0.28 indicating that Centene is being referred to more favorably in the news media.
92.4% of Humana shares are owned by institutional investors. Comparatively, 93.6% of Centene shares are owned by institutional investors. 0.3% of Humana shares are owned by company insiders. Comparatively, 0.3% of Centene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Centene has higher revenue and earnings than Humana. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.
Summary
Humana beats Centene on 10 of the 18 factors compared between the two stocks.
Get Humana News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
